Bryn Mawr Capital Management LLC Sells 23,709 Shares of The Chemours Company (NYSE:CC)

Bryn Mawr Capital Management LLC lessened its stake in shares of The Chemours Company (NYSE:CC - Free Report) by 89.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,756 shares of the specialty chemicals company's stock after selling 23,709 shares during the period. Bryn Mawr Capital Management LLC's holdings in Chemours were worth $47,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. boosted its position in Chemours by 166.9% in the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock worth $26,000 after purchasing an additional 731 shares in the last quarter. GAMMA Investing LLC grew its holdings in Chemours by 99.7% in the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 765 shares during the period. Truvestments Capital LLC purchased a new stake in shares of Chemours in the third quarter valued at approximately $35,000. Brooklyn Investment Group acquired a new position in shares of Chemours during the 3rd quarter worth approximately $37,000. Finally, Signaturefd LLC boosted its holdings in Chemours by 163.7% in the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock worth $40,000 after buying an additional 1,216 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Trading Up 1.2 %

CC stock traded up $0.19 during trading on Wednesday, reaching $15.99. 1,201,728 shares of the stock traded hands, compared to its average volume of 1,806,125. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The Chemours Company has a 52-week low of $14.94 and a 52-week high of $29.44. The firm has a market capitalization of $2.39 billion, a PE ratio of 28.09 and a beta of 1.81. The business's 50 day moving average price is $17.99 and its 200-day moving average price is $18.89.

Remove Ads

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The company had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.37 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. As a group, sell-side analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 14th. Stockholders of record on Friday, February 28th will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 6.26%. The ex-dividend date of this dividend is Friday, February 28th. Chemours's dividend payout ratio (DPR) is currently 175.44%.

Analysts Set New Price Targets

Several analysts have recently weighed in on CC shares. BMO Capital Markets dropped their price target on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research note on Wednesday, February 19th. Barclays lowered their price target on Chemours from $23.00 to $19.00 and set an "equal weight" rating for the company in a report on Monday. Morgan Stanley decreased their target price on shares of Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Mizuho cut their price objective on Chemours from $22.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. Finally, The Goldman Sachs Group lowered their target price on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $23.11.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.